One of the ongoing goals of every publicly held biotechnology company is to get its story in front of interested investors. But in a unverse of almost 6,000 mutual and pension funds, only a handful of core investors who specialize in health care and biotech are immediately identifiable, and even they have specific likes and dislikes that could make the difference between a company finding a good match and coming up empty.

The trick is to put together companies and investors that fit each others' profiles without wasting either side's time. In biotech that's not always easy, because the traditional criteria by which most funds screen companies don't hold up for this sector.